ArticleNeurotrauma reports2025
PAR-1 Expression in Chronic Subdural Hematoma: Potential Association with Vascular Permeability.
Article in Neurotrauma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Atorvastatin accelerates hematoma absorption and ameliorates cognitive impairment in patients with chronic subdural hematoma complicated by cognitive dysfunction: a retrospective analysis.Frontiers in pharmacology · 2026Article
- Parasagittal subdural space: a novel quantitative marker of spontaneous intracranial hypotension syndrome-induced chronic subdural hematoma.BMC medical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic subdural hematoma (CSDH) is a common neurosurgical disease in the elderly, characterized by inflammation, neovascularization, and increased vascular permeability. Although protease-activated receptor-1 (PAR-1) is known to regulate vascular permeability and is implicated in chronic inflammatory diseases, its role in CSDH remains unclear. In this exploratory study, we investigated PAR-1 expression in the dura mater and outer membrane of patients with CSDH compared with controls. Age- and sex-matched cases (six CSDH, five controls) were selected for analysis. Immunohistochemistry for PAR-1 and zonula occludens-1 (ZO-1), along with mRNA expression analysis, were performed. Histologically, the outer membrane of CSDH exhibited cellular clustering and strong PAR-1 immunoreactivity in vascular structures, whereas the dura mater from both groups showed no significant PAR-1 staining. ZO-1 expression was preserved in the vasculature of the outer membrane in CSDH and the dura mater of both groups. mRNA analysis revealed a trend toward higher PAR-1 and lower ZO-1 expression in CSDH, though not statistically significant. The group effect (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.